This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Marinus Pharmaceuticals’s 8K filing here.
Marinus Pharmaceuticals Company Profile
Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.
Featured Stories
- Five stocks we like better than Marinus Pharmaceuticals
- Special Purpose Acquisition Company (SPAC) What You Need to Know
- Rivian’s Wild Ride: Is the Dip a Buying Opportunity?
- The Significance of a Trillion-Dollar Market Cap Goes Beyond a Number
- Freshworks Stock Soars 50% – Is This the Perfect Entry Point?
- Golden Cross Stocks: Pattern, Examples and Charts
- Why Meta Should Rally All The Way Into 2025
